$5 HCV drugs may be effecting profits

Gilead Sciences in its second-quarter report for 2017 reported that its sales of direct-acting antivirals for HCV were down about 25 percent from the same period last year (2.9 billion, compared with 4 billion). Does this mean that fewer cases of HCV are being treated, or does it mean the prices of antivirals are going down?

It’s hard to compare the prices because the company is secretive about its negotiations with insurance companies and governments. When the drugs were first on the market, wealthy patients were shelling out upwards of $100,000 for the drugs. Now, except for uninsured people or those on Medicare or Medicaid, Gilead is advertising a $5 bargain price for the drugs. Considering the exclusions, that doesn’t seem like charity, but it may be keeping Gilead’s cash coffers down.

As for the numbers of people being treated, the latest report from the World Hepatitis Alliance shows they’ve more than doubled since 2013, when 440,000 people were treated, mainly with interferon.

Advertisements

Book about Hepatitis C now available, will talk about Demon in My Blood at May & June events

Demon in My Blood is off the press, in book stores and on Amazon.ca and Amazon.com. The book tells the story of my bout with hepatitis C, my cure, the development of direct-acting antivirals, the accessibility of the drugs, and the quest to learn how I acquired the disease. Demon in My Blood can be read as a history of medical innovation, a patient-experience chronicle, or a mystery. It’s also a cry for widespread testing.

The book will be launched in two locations:

Vancouver
Wednesday, May 31, 2017, 7 pm
Book Warehouse
Main Street and King Edward Avenue

Gibsons
Friday, June 16, 2017, 7 pm
Truffles Cafe
264 Gower Point Road

I’ll be reading and speaking about the book. There will be light refreshments and a door prize at each location. I hope to see you there.

The liver is important–so get out the hep C testing message

As Hepatitis Awareness Month continues, it’s time to think more about testing for hepatitis C. The disease is curable, but the liver, if too severely damaged, is not.

Everyone who has hep, had hep, works with people who have hep C or is reading this blog because of other interests, should pass the testing message along. It’s vital, just like the liver.

Hepatitis C ravages the liver. It’s symptoms usually creep up sluggishly and at first, imperceptibly. That’s why most people with the chronic form of the disease don’t know they have it. That’s why feeling symptoms of hep C should not be the only reason to be tested.

Being a baby baby boomer or suspecting you have been in contact with someone else’s unscreened blood should be the reason.

You can’t live without a liver. It filters blood, removing harmful substances, such as alcohol. It manufactures proteins that defend against infection and help the blood to clot. It regulates the supply of vitamins, minerals, and hormones, including sex hormones. It produces, stores, and regulates glucose and fat. It makes and eliminates cholesterol and also converts it into lipoproteins that deliver energy to the cells.

Altogether, the liver performs more than five hundred bodily functions. It continues to do these jobs during the early stages of hep-caused fibrosis, and early on it can recover fully from damage. Later, when the liver hardens into cirrhosis, it progressively loses important abilities. When the damage becomes severe, liver cancer or a liver transplant are common results.

So no one should risk this vital organ, whether they have symptoms of hep C or not. It’s easy to get tested. Just ask your doctor–or ask your friends to ask theirs.

May is on the way with hepatitis C awareness

May is Hepatitis Awareness Month. As the month begins, it’s a good time to mark your calendar with an important date. May 19 is Hepatitis Testing Day.

As a reader of this blog, you’ve probably already been tested. Many readers are dealing with their own virus or have friends who have hep C. Other readers are medical professionals, and still others, I’m glad to say, have been cured.

But not everyone has. You can’t be cured if you don’t know you have hep. Let’s all try to mark the month by thinking of those who have yet to be tested, especially Baby Boomers. Please tell your friends about the month and the testing day.

‘The Sovaldi of rare diseases’ on the market for children

For the two years I’ve been writing this blog, I’ve stuck to stories specifically about hepatitis C. Some were critiques of the high prices charged for hep C drugs.Today I’ve learned that the $100,000 or so required to rid patients of the liver killing disease has been topped by far by a drug that can save children’s lives—if their parents can afford millions of dollars for treatment.So I’m writing about a new (not for hepatitis) drug, Spinraza.

The drug maker Biogen has just gained U.S. approval for Spinraza. Injected directly into the spine, Spinraza can halt or even reverse spinal muscular atrophy. SMA afflicts babies and children. They progressively lose muscle control and die, usually before age 20 and often as toddlers or infants. SMA is the leading cause of death in infants. Spinraza costs $750,000 U.S. per year for the first year of treatment, and $375,000 per year after that.

Biogen, like the companies that developed drugs for hepatitis C, can be applauded for its research on the breakthrough SMA drug. But like hep C drug makers, Biogen is charging far too much.

Interestingly, healthcare analyst Geoffrey Porges, called Spinraza “the Sovaldi of rare disease drugs” Porges is an analyst for Leerink, a healthcare investment bank. He made the statement to the biotech publication Endpoints News. Gilead’s Sovaldi set the pace in drug pricing in its 2014 rollout of Solvaldi. The hep C treatment cost patients $84,000 for eight weeks of pills that were combined with interferon or simeprevir. Although the cost of Solvaldi and other hep C drugs has decreased somewhat in the past two years, many, many patients still cannot afford treatment.

Now there’s a much costlier drug that can keep helpless children from dying. One can imagine the dollar signs in the eyes of Biogen shareholders—and the tears in the eyes of parents who cannot afford the drug.